Comparative Pharmacology
Head-to-head clinical analysis: REGROTON versus SERPASIL APRESOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGROTON versus SERPASIL APRESOLINE.
REGROTON vs SERPASIL-APRESOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases cGMP via NO).
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination